Archive - April 2019
-
Dosage regime relief!
11 April 2019Read more >A unanimous decision by the Supreme Court is being hailed as a relief for innovators in the pharmaceutical sector, and confirms that novel and inventive dosage regimes are patentable. Tadalafil (Cialis) is a second in class PDE5 inhibitor for the treatment of erectile dysfunction. This use of tadalafil was first disclosed in EP 0839040 (the […]
